CO6390112A2 - Método para el tratamiento de la enfermedad de parkinson usando un bacterófago filamentoso - Google Patents

Método para el tratamiento de la enfermedad de parkinson usando un bacterófago filamentoso

Info

Publication number
CO6390112A2
CO6390112A2 CO11078816A CO11078816A CO6390112A2 CO 6390112 A2 CO6390112 A2 CO 6390112A2 CO 11078816 A CO11078816 A CO 11078816A CO 11078816 A CO11078816 A CO 11078816A CO 6390112 A2 CO6390112 A2 CO 6390112A2
Authority
CO
Colombia
Prior art keywords
disease
parkinson
bacterophagus
filament
treatment
Prior art date
Application number
CO11078816A
Other languages
English (en)
Spanish (es)
Inventor
Beka Salomon
Haim M Dimant
Original Assignee
Ramot At Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot At Tel Aviv University Ltd filed Critical Ramot At Tel Aviv University Ltd
Publication of CO6390112A2 publication Critical patent/CO6390112A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/859—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from immunoglobulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CO11078816A 2008-11-24 2011-06-23 Método para el tratamiento de la enfermedad de parkinson usando un bacterófago filamentoso CO6390112A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11744608P 2008-11-24 2008-11-24

Publications (1)

Publication Number Publication Date
CO6390112A2 true CO6390112A2 (es) 2012-02-29

Family

ID=41572327

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11078816A CO6390112A2 (es) 2008-11-24 2011-06-23 Método para el tratamiento de la enfermedad de parkinson usando un bacterófago filamentoso

Country Status (16)

Country Link
US (1) US20110286970A1 (cg-RX-API-DMAC7.html)
EP (2) EP2478911A1 (cg-RX-API-DMAC7.html)
JP (1) JP2012509672A (cg-RX-API-DMAC7.html)
KR (1) KR20110091778A (cg-RX-API-DMAC7.html)
CN (1) CN102223887B (cg-RX-API-DMAC7.html)
AU (1) AU2009316326A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0921557A2 (cg-RX-API-DMAC7.html)
CA (1) CA2744339A1 (cg-RX-API-DMAC7.html)
CO (1) CO6390112A2 (cg-RX-API-DMAC7.html)
IL (1) IL213120A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011005430A (cg-RX-API-DMAC7.html)
NZ (1) NZ592928A (cg-RX-API-DMAC7.html)
RU (1) RU2011125971A (cg-RX-API-DMAC7.html)
SG (1) SG171791A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010060073A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201104701B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2102239T3 (da) * 2006-11-30 2012-05-29 Res Dev Foundation Forbedrede immunoglobulin-biblioteker
US20110182948A1 (en) * 2008-05-22 2011-07-28 Beka Solomon Method for treating disease characterized by plaque
BR112013023040A2 (pt) 2011-03-11 2018-10-23 Univ Ramot bacteriófago filamentoso, composição farmacêutica, e, métodos para reduzir a formação de fibrilas de proteína tau ou para desagregar fibrilas pré-formadas de proteína tau em um paciente, e para tratar uma tauopatia degenerativa.
EP2736522A1 (en) 2011-07-27 2014-06-04 Neurophage Pharmaceuticals, Inc. Process for the production of filamentous bacteriophage
US9493515B2 (en) 2011-11-29 2016-11-15 Proclara Biosciences, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
EA033666B1 (ru) 2012-10-02 2019-11-14 Proclara Biosciences Inc Амилоидсвязывающие белки и их применение
JP2016526044A (ja) 2013-05-28 2016-09-01 ニューロファージ ファーマシューティカルズ, インコーポレイテッド 低減された免疫原性を有する修飾されたバクテリオファージg3pアミノ酸配列を含むポリペプチド
KR20170085132A (ko) 2014-12-03 2017-07-21 프로클라라 바이오사이언시즈, 인크. 글리코실화 신호가 결핍된 변형된 박테리오파지 g3p 아미노산 서열을 포함하는 폴리펩티드

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003509020A (ja) * 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
WO2002042321A2 (en) * 2000-11-24 2002-05-30 Isis Innovation Limited Mixed fibrils
IL163812A0 (en) * 2002-03-05 2005-12-18 Univ Ramot Immunizing composition and method for inducing an immune response against the -secretase cleavage site of amyloid precursor protein
GB0305918D0 (en) * 2003-03-14 2003-04-23 Glaxo Group Ltd Novel compounds
FR2855178B1 (fr) * 2003-05-20 2005-08-05 Centre Nat Rech Scient Peptides modulateurs de l'activite du facteur de transcription engrailed
CA2593846A1 (en) * 2005-01-14 2006-08-10 The Regents Of The University Of California Compositions and methods for inhibiting drusen formation and for diagnosing or treating drusen-related disorders
JP5096169B2 (ja) * 2005-02-01 2012-12-12 ラモット・アット・テルアビブ・ユニバーシティ アミロイド沈着に付随する炎症および活性化されたマイクログリアにかかわる脳の炎症の処置法
MX2008010612A (es) * 2006-02-15 2009-03-20 Ramot At Tel Aviv University Bacteriofago filamentoso que exhibe proteina a como aglutinante de anticuerpos e inmunocomplejos para el suministro hacia el cerebro.
US20090324554A1 (en) * 2006-07-21 2009-12-31 Ramot At Tel Aviv University Ltd. Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar or aggregates
US20110182948A1 (en) * 2008-05-22 2011-07-28 Beka Solomon Method for treating disease characterized by plaque

Also Published As

Publication number Publication date
AU2009316326A1 (en) 2010-05-27
MX2011005430A (es) 2011-10-28
ZA201104701B (en) 2012-09-26
HK1162964A1 (en) 2012-09-07
SG171791A1 (en) 2011-07-28
EP2478911A1 (en) 2012-07-25
JP2012509672A (ja) 2012-04-26
US20110286970A1 (en) 2011-11-24
NZ592928A (en) 2012-12-21
IL213120A0 (en) 2011-07-31
CN102223887A (zh) 2011-10-19
EP2358377A2 (en) 2011-08-24
KR20110091778A (ko) 2011-08-12
WO2010060073A2 (en) 2010-05-27
WO2010060073A3 (en) 2010-09-02
CA2744339A1 (en) 2010-05-27
BRPI0921557A2 (pt) 2019-09-24
CN102223887B (zh) 2013-11-06
RU2011125971A (ru) 2012-12-27

Similar Documents

Publication Publication Date Title
AR119754A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
CU24058B1 (es) Antagonistas de pcsk9
ES2722300T3 (es) Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso
CY1116488T1 (el) Αντισωματα anti-προπερδινης
CR20110606A (es) Uso de un anticuerpo anti-tau ps422 para el tratamiento de enfermedades cerebrales
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
PA8847001A1 (es) Anticuerpos humanos de alta afinidad para el receptor il-4-humano
CL2011000269A1 (es) Anticuerpo o fragmento del mismo que se une a cd127; y metodo de tratamiento de enfermedad autoinmune o un trastorno inflamatorio en humanos, que comprende administrar un antagonista de al menos una de la expansion de th17 mediada por el receptor de il-7 y la supervivencia de th17 mediada por el receptor de il-7.
CR20120310A (es) Anticuerpos neutralizadores contra el receptor de prolactina y su uso terapéutico
CR20120086A (es) Anticuerpos humanos de alta afinidad para la angiopoyetina-2 humana
MX2021011167A (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
BRPI0813237B8 (pt) composto, método para preparar o composto, medicamento, e, uso do composto
AR096895A2 (es) Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)
UA111818C2 (uk) Антитіло проти csf-1r
UA109633C2 (uk) Антитіло людини проти тканинного фактора
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
CL2011000043A1 (es) Compuestos derivados de benzoazepina sustituidos; compuestosintermediarios; metodo de sintesis; composicion farmaceutica; y uso en el tratamiento o prevencion de un trastorno del sistema nervioso central.
NI200700315A (es) Anticuerpos monoclonales anti-trkb y usos de los mismos.
UY32883A (es) Anticuerpos humanos de alta afinidad contra el receptor activado por proteasa de tipo 2 humano
SV2011004043A (es) Composiciones y metodos para aumentar el crecimiento muscular
EA200802182A1 (ru) Модифицированные гуманизированные антитела против интерлейкина-18
ECSP11010748A (es) Antagonistas específicos del receptor fgf-r4
GT200600046A (es) Terapia de combinacion
CL2008001238A1 (es) Anticuerpo antagonista aislado anti-receptor grig/pro362/jam4/stigma murino con numero de deposito atcc pat-8298; composicion farmaceutica; uso medico para inhibir la entrada celulst dependiente del complemento mediada por crig de un patogeno intracelular (pi), o para prevenir o tratar una enfermedadad infeccionsa mediada por un pi

Legal Events

Date Code Title Description
FA Application withdrawn